Background
==========

Malaria affects about one quarter of a billion people annually, with up to two-thirds of a million deaths still occurring per year, particularly in sub-Saharan African children below five years of age \[[@B1]\]. Why only a small proportion (1--3%) of *Plasmodium falciparum* infections progress to severe or fatal episodes \[[@B2]\] while others remain asymptomatic or develop an uncomplicated illness is not yet fully understood. Epidemiological data indicate that about 25% of the risk to *Plasmodium* infection in Africa is determined by human genetic factors \[[@B3]\]. Nevertheless, haemoglobin S, the strongest known resistance genetic factor, explains only 2% of the total variation \[[@B3]\], suggesting the existence of many unknown protective genes, each individually having small population effects. Single-nucleotide polymorphisms (SNPs) comprise a large part of human diversity, and their inheritance may alter susceptibility to disease \[[@B4]\].

Many of the malaria protective associations described to date relate to genes that affect cytokine and toll-like gene expression \[[@B5],[@B6]\], red blood cell (RBC) structure or function \[[@B7]\]. However, there are a number of interesting candidate polymorphisms that have been associated with other infectious diseases and may be linked to malaria pathogenesis. Complement factor 6 (*C6*), for instance, shows polymorphism resulting in deficiency of the protein \[[@B8]\] although its role in malaria has not been proven. The susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (*CFTR*) \[[@B9]\], while genetic associations of a member of the tripartite motif (*TRIM*) family with human immunodeficiency virus type 1 infection \[[@B10]\] have been reported. The levels of reticulon 3 (*RTN3*) is significantly increased in malaria and other infections \[[@B11]\] suggesting that it may be linked to the disease.

The effect of some polymorphisms on malaria pathogenesis still remains controversial. There was no association between intercellular adhesion molecule 1 gene polymorphisms and severe malaria in a West African population \[[@B12]\], although the SNP had earlier been reported to predispose to cerebral malaria in Kenya \[[@B13]\]. The *NOS2A*-954C allele has been associated with protection from severe malaria in Gabonese individuals \[[@B14],[@B15]\], but studies in The Gambia and Tanzania failed to detect such a disease association \[[@B16],[@B17]\]. Additionally, the *NOS2A*-1173 T allele which appears, on the basis of measurements in urine and plasma, to be associated with high NO production in children is associated with protection from malarial illness in Tanzania and from severe malarial anaemia in Kenya \[[@B18]\], but no protective effect against severe malaria was detected in The Gambia \[[@B17]\].

Several studies have demonstrated the critical role of anti-inflammatory cytokines in the immuno-pathogenesis of severe malaria anaemia (SMA) and cerebral malaria (CM). *Plasmodium chabaudi chabaudi* infected mice deficient in interleukin-10 (IL-10) show higher mortality than their normal littermates \[[@B19]\], suggesting a protective role for this cytokine. Furthermore, IL-10 seems to induce and maintain immunity to *P. falciparum* in naturally exposed populations \[[@B20]\]. Importantly, the down regulation of TNF-α production and consequent resistance to severe malaria, has been linked to the ability to produce the immuno-regulatory cytokine, Transforming growth factor (TGF)-β \[[@B21]\]. Low levels of IL-10 and TGF-ß have been associated with severe malaria \[[@B22],[@B23]\]. Functional polymorphisms in the promoter and/or coding region(s) of cytokine genes may, therefore, be crucial in the development and clinical course of malaria \[[@B5]\]. Indeed, polymorphisms in genes encoding IL-10 \[[@B6],[@B24]\] have been associated with susceptibility to malaria, although their functional role in severe malaria still remains open to question. How the levels of these cytokines vary in different haemoglobin β-globin and other malaria candidate SNP genotypes, therefore, warrants further investigation.

Case--control studies have been vital in detecting several genes associated with malaria or severe malaria \[[@B6],[@B25]-[@B27]\]. However, some reports have been contradictory, due partly, to the analysis of small sample numbers, and hence limited statistical power. Furthermore, differences in transmission intensities or other epidemiologic characteristics at the different sites and ethnicities may affect the detection of modest effects of susceptibility or resistance genes. Some rare SNPs were investigated in a case--control study among 971 children with malaria and 891 unmatched apparently healthy control school children and blood bank donors in a bid to identify novel ones that may be linked to malaria and TGF-ß and IL-10 levels.

Methods
=======

Study area
----------

This cross-sectional study was conducted in four towns distributed in three regions of Cameroon, namely: Yaoundé in the Centre; Douala in the Littoral; and Buea and Limbe in the South West. The study sites included hospitals (Bota District Hospital - Limbe, Laquintinie Hospital - Douala, Mother and Child Hospital -- Yaoundé, Regional Hospital - Limbe and Regional Hospital - Buea) and health centres (Bokova Health Centre, Mount Mary Health Centre - Buea and PMI Down Beach - Limbe). All chosen health facilities, except Mount Mary, were the main government institutions in the selected towns, also receiving patients from surrounding areas. Although malaria is endemic throughout Cameroon, the country has very different geographical and epidemiologic strata that may alter the course of the infection. In general, malaria transmission is intense and perennial in the Centre, Littoral (Coastal), and South Western regions, with peak periods corresponding to the rainy seasons \[[@B28]\].

The Centre region (Yaoundé) is located within the rainforest belt of central Africa \[[@B29]\] and has the Guinea-type equatorial climate \[[@B28]\]. This is characterized by fairly constant temperatures \[ranging from 17°C to 30°C (mean = 23.1°C)\] \[[@B30]\], abundant rainfall (1,500--2,000 mm), with the average relative humidity index ranging from 85% to 90%, and four distinct seasons: two rainy seasons (March -- May/June, September -- November) and two dry seasons (December -- February, June/July -- August). Maximal transmission of malaria occurs during and immediately following the two rainy seasons \[[@B28]-[@B30]\]. The Mother and Child Hospital is a referral hospital for children and mothers, located in the heart of the city of Yaoundé; it also attracts patients from neighbouring villages such as Simbok and Etoa that are stable, rural, farming communities with fields irrigated by water from the Mefou and Biyeme Rivers. Inhabitants of this region are of the Ewondo tribe and part of the Bantu ethnic group.

The South Western and Littoral regions have a Cameroonian-type equatorial climate characterized by fairly constant temperatures and two seasons: a short dry season (November -- March) and a long rainy season (March - November) with abundant precipitation (2,000--10,000 mm) \[[@B28]\]. In the Mt Cameroon region of the South West, the mean annual rainfall is 2625 mm, relative humidity is constantly high (75%--80%), and the temperature varies from 18°C in August to 35°C in March \[[@B31]\]. Human malaria is meso-endemic during the dry season but becomes hyper-endemic in the rainy season, with incidence peaking in July--October. The prevalence of malaria parasitaemia in the low-altitude areas ranges from 30% in the dry season to 84% in the rainy season \[[@B32],[@B33]\]. *Plasmodium falciparum* accounts for up to 96% of malaria infections in this area \[[@B34]\], with *Anopheles gambiae s.s.* the dominant vector \[[@B31]\].

Study design and population
---------------------------

The study conducted between 2003/05 and 2007/08 involved malaria diagnosed children (aged 1 month -- 13 years) admitted in nine health facilities in the Centre, Littoral and South West regions of Cameroon \[[@B35]\]. The 971 unrelated sick children sampled included severe and uncomplicated malaria cases, mainly from the Bantu and Semi-Bantu ethnic groups, recruited from the paediatric wards of the hospitals or health centres (Figure [1](#F1){ref-type="fig"}). In line with WHO guidelines \[[@B36]\], severe malaria was defined by the presence of asexual *Plasmodium* parasitaemia and at least one of the following conditions: cerebral malaria (CM) \[impaired consciousness or unrousable coma (Blantyre coma score ≤ 2) and no record of recent severe head trauma, neurological disease or any other cause of coma\]; severe malaria anaemia (SMA) \[haemoglobin \< 5 g/dL or haematocrit \< 15%, no cases of severe bleeding or observed convulsions\]; hyperpyrexia (axillary temperature ≥ 40°C); hyperparasitaemia (\>250,000 parasites/μL); convulsions before/during admission; respiratory distress (RD) (presence of alar flaring, intercostals or subcostal chest recession, use of accessory muscles of respiration, or abnormally deep respiration) and hypoglycaemia (blood glucose \<2.2 mmol/L/40 mg/dl). Participants with co-existing severe or chronic medical conditions (e.g. bacterial pneumonia, kwashiorkor) unrelated to a severe malarial infection were excluded. UM was defined as a clinical illness characterized by an axillary temperature ≥37.5°C associated with a *Plasmodium* positive blood film, haemoglobin ≥ 8 g/dL and full consciousness, in the absence of clinical signs and symptoms of severe malaria and/or evidence of vital organ dysfunction.Controls (n = 891) consisted of apparently healthy children (aged 1-14 years, afebrile and free from any obvious illness) and adults (aged 17-52 years, asymptomatic, from the community) also belonging primarily to the Bantu and Semi-Bantu ethnic groups (Figure [1](#F1){ref-type="fig"}). Children were recruited during malaria cross-sectional surveys from primary schools located in the South West region (Buea Metropolis) between 2004-2005 and 2007-2008. Children with parasitaemia and a temperature of 37.5°C or above were not recruited as controls. Adults were identified from a blood bank in the Centre region (Mother and Child Hospital - Yaounde) between July and August 2007. These controls were thought to approximate a random sample of the population thus, reflecting the true allele frequency. Data on the Foulbe ethnic group who constitute a significant proportion of the ethno-demographics of Cameroon were not included in the final analysis because of their small sample size in the study population.

![Basic demographic characteristics of the cases (n = 971) and controls (n = 891) in the study.](1475-2875-13-236-1){#F1}

Ethical approvals
-----------------

Ethical and administrative clearance for the study was obtained from the University of Buea Institutional Review Board and the South West Regional Delegation of Public Health respectively. Authorization to conduct the surveys in designated primary schools was obtained from the Regional Delegation of Basic Education or the Catholic Education Secretariat of the South West Region. Individuals who fulfilled the specific inclusion criteria and volunteered to participate after adequate sensitisation on the project objectives, methods and possible benefits/risks were enrolled in to the study. A health facility or school was only investigated with the approval of its Director or Head Teacher and study participants were only enrolled if they or their caregivers/guardians gave written informed consent/assent.

Malaria parasitaemia determination
----------------------------------

Thick and thin blood smears were prepared following standard procedures and stained with 5% Giemsa (Sigma, St. Louis, USA). The malaria parasitaemia status and density were determined under oil immersion with the 100x objective, 10x eyepiece of a binocular Olympus microscope (Olympus Optical Co., Ltd, Japan) while the *Plasmodium* species was identified on the thin blood smear. A smear was only considered negative if no malaria parasites were seen in 50 high power fields. With each positive smear, the level of parasitaemia was estimated by counting the parasites against at least 200 leucocytes and using the corresponding leucocyte count to calculate the number of parasites/μl blood \[[@B37]\].

Cytokine measurement
--------------------

Plasma levels of IL-10 and TGF-β were measured in cases and controls by Enzyme-Linked Immunosorbent Assay (ELISA), according to the manufacturer's instructions (Quantikine R&D systems). Samples were obtained at the time of admission (CM/SMA), outpatient treatment (UM), or enrollment (Controls). The results were expressed in pg/ml by reference to standard curves prepared in each plate with recombinant cytokines. In all, the ELISAs, standards/samples were run in duplicates, and tested 10 non-immune Swedish & British sera were used as negative controls to check that the response was specific to malaria infection.

Selection of SNPs and genotyping
--------------------------------

Genomic DNA was extracted from whole blood or packed cells using the Promega Wizard (Promega Corporation, Madison, USA) or Nucleon™ BACC Genomic DNA Extraction (Gen-Probe Life Sciences, Manchester, UK) kits and quantified by the picogreen assay. The DNA samples were whole-genome amplified by Primer Extension Pre-amplification \[[@B38]\] before genotyping on the Sequenom IPLEX genotyping platform (Sequenom Inc., San Diego, USA) \[[@B39]\]. Polymorphism sequence information was downloaded from Ensembl (<http://www.ensembl.org>) and reformatted for the assay design process (<http://www.sequenom.com>). Multiplex design for the iPLEX methodology was then undertaken using the MassARRAY^®^ Assay Design v3.1 Software and the resulting multiplexes tested using a panel of CEPH and YRI HapMap DNAs. Thirty-four malaria candidate polymorphisms in various genes including *GBP7*, *DARC*, *CR1*, *C6*, *CTL4*, *NOD1*, *CD36*, *CFTR*, *ABO*, *HBB*, *HbC*, *TRIM5*, *RTN3*, *SPTB*, *ADCY9*, *ADORA2B*, *NOS2*, *EMR1*, *ICAM1*, *GNAS*, *DERL3*, *CD40LG* and *G6PD* were genotyped in 971 cases and 891 controls. The SNPs were compiled on the basis of a review of reports of associations with severe malaria or association with other infectious diseases. The haemoglobin variant S (HbS) polymorphism, known to be strongly associated with severe malaria \[[@B25],[@B40]\] was also genotyped. Genotype calling was performed using the Sequenom Spectro-typer software, an automated algorithm, followed by a careful visual inspection of the genotype cluster plots to assess quality. All the assays were quality filtered (call rate \> 90%) and assessed for evidence of genotypic deviation from Hardy--Weinberg equilibrium (HWE) in the controls (P \< 0.001), indicative of genotyping error \[[@B41]\].

Data analyses
-------------

Statistical analyses were performed using IBM SPSS Statistics 17.0 (IBM Corporation, NY, USA) and the R software package (<http://www.r-project.org>). Genotypic deviations from HWE were assessed using a Chi-square statistical test. Case--control association analysis of SNP alleles and genotypes was undertaken by logistic regression with self-reported ethnicity age, sex and the *HbS* polymorphism included as covariates. Adjustment for self-reported ethnicity has been found to be a robust approach to controlling the potentially confounding effects of population structure \[[@B25]\]. Performing multiple statistical tests can lead to an increased chance of false positives. Also, as there are multiple polymorphisms in some genes, some statistical tests will be correlated. Thus, for the genetic results, a simulation was performed by permuting the phenotypes 10000 times to establish a significance cut-off, and found a threshold of *p* ≤ 0.01 to be equivalent to a nominal false positive rate of 5%.

Results
=======

A total of 971 cases and 891 controls were enrolled into the study. The mean age (±standard deviation) of the cases and control children was 55.4 ± 37.9 and 87.7 ± 22.9 months respectively. The basic demographic characteristics of the study population (Figure [1](#F1){ref-type="fig"}) indicates a fairly gender balanced distribution in the cases \[453 (46.7%) females vs. 516 (53.3%) males\] that were enrolled mainly from the South West region \[515 (53.3%)\] and from the Semi-Bantu \[416 (50.0%)\] and Bantu \[385 (46.3%)\] ethnic groups. The most prevalent clinical phenotypes included severe malaria anaemia \[n (%), 248 (21.8)\], uncomplicated malaria \[252 (22.1)\], hyperpyrexia \[116 (15)\], hyperparasitaemia \[58 (6.5)\] and cerebral malaria \[51 (5.4)\].

Three polymorphisms were removed from the analysis because they were monomorphic (7:080302110, rs33950507, rs1799969) while two of the assays did not pass the quality filters (call rate \> 90%, rs8176719, rs33930165), leaving 30 SNPs that could be analysed for their association with malaria phenotype (Table [1](#T1){ref-type="table"}). There was no evidence of genotypic deviation from HWE in the controls (p \> 0.06). Additional file [1](#S1){ref-type="supplementary-material"} shows the minimum p-values from allelic/genotypic tests applied to the autosomal SNPs, and confirms that the sickle cell (HbS) polymorphism (rs334) was significantly associated with protection from malaria infection \[AT *vs.* AA/TT, odds ratio (OR) = 0.29, 95%CI 0.21-0.42, p = 4.95 × 10^-13^\] and from SMA \[AT vs. AA/TT, OR = 0.34, 95%CI 0.13-0.93, p = 0.024\] (Table [2](#T2){ref-type="table"}).

###### 

Minor allele frequencies and test of Hardy-Weinberg equilibrium in selected candidate SNPs

    **Gene**     **Alternate SNP name**    **SNP**     **Location**   **Minor allele frequency**   **HWE**^**†**^          
  ------------- ------------------------ ------------ -------------- ---------------------------- ---------------- ------- ----------
       HBB                HbS               rs334         Genic                  A/T                   0.054        0.088    0.189
      GBP7                                rs1803632         P                    C/G                   0.474        0.497    0.074
      DARC                                rs2814778        UTR                   A/G                   0.006        0.003    1.000
       CR1                                rs17047660       UTR                   A/G                   0.283        0.301    0.409
       CR1                                rs17047661      Genic                  G/A                   0.277        0.272    0.379
       C6                                 rs1801033       Genic                  A/C                   0.415        0.417    0.515
      CTL4                                rs2242665       Genic                  A/G                   0.319        0.324    0.642
      NOD1                                rs2075820         P                    G/A                   0.401        0.397    0.170
      CD36                                rs3211938       Genic                  T/G                   0.144        0.148    0.409
      CFTR                                rs17140229      Genic                  C/T                   0.401        0.408    0.129
       ABO                                rs8176746       Genic                  C/A                   0.166        0.170    0.173
      TRIM5                               rs7935564       Genic                  G/A                   0.486        0.486    0.273
      RTN3                                 rs542998       Genic                  C/T                   0.379        0.384    0.375
      SPTB                                 rs229587       Genic                  T/C                   0.290        0.291    0.669
      ADCY9                               rs2230739       Genic                  A/G                   0.092        0.104    0.434
      ADCY9                               rs10775349      Genic                  C/G                   0.151        0.169    0.462
     ADORA2B                              rs2535611       Genic                  T/C                   0.099        0.110    0.715
      NOS2                                rs2297518       Genic                  G/A                   0.105        0.139    0.552
      NOS2              NOS2-954          rs1800482        UTR                   G/C                   0.082        0.080    0.812
      NOS2                                rs9282799        UTR                   C/T                   0.040        0.036    0.076
      NOS2             NOS2-1659          rs8078340        UTR                   C/T                   0.270        0.280    0.200
      EMR1                                 rs373533       Genic                  G/T                   0.444        0.463    0.942
      EMR1                                 rs461645       Genic                  C/T                   0.446        0.468    1.000
      ICAM1          ICAM-1codon469         rs5498        Genic                  A/G                   0.119        0.141    0.238
      GNAS             GNAS_8386            rs8386        Genic                  C/T                   0.159        0.154    0.224
      DERL3                               rs1128127       Genic                  A/G                   0.464        0.457    0.481
   CD40LG~(F)~                            rs3092945         P                    T/C                   0.295        0.269    0.359
   CD40LG~(M)~                            rs3092945         P                    T/C                   0.295        0.257   \< 0.001
   CD40LG~(F)~                            rs1126535       Genic                  T/C                   0.188        0.161    0.190
   CD40LG~(M)~                            rs1126535       Genic                  T/C                   0.159        0.216   \< 0.001
    G6PD~(F)~                             rs1050829         P                    T/C                   0.360        0.333    0.342
    G6PD~(M)~                             rs1050829         P                    T/C                   0.360        0.341   \< 0.001
    G6PD~(F)~                             rs1050828         P                    C/T                   0.031        0.089    0.711
    G6PD~(M)~                             rs1050828         P                    C/T                   0.120        0.106   \< 0.001

*UTR* 3'untranslated region, *P* promoter, Maj/Min = Major/Minor allele**,** M = male, F = Female ^**†**^One degree of freedom *χ*2 test of HWE applied to the 891 controls.

###### 

Genotype associations between selected SNP and syndromes of malaria

     **Phenotype**      **Gene**       **SNPs**        **Model**        **Genotypes**     **OR**   **95%CI**   **P value**^**‡**^  
  ------------------- ------------- -------------- ------------------ ------------------ -------- ----------- -------------------- -------
        Anemia            hHbS          rs334         Heterozygous       AT vs. AA/TT      0.50      0.31             0.80          0.004
         GBP7           rs1803632    Heterozygous     CG vs. GG/CC           1.42          1.05      1.91            0.023         
         CFTR          rs17140229      Additive     TT vs. CT vs. CC         0.78          0.62      0.97            0.026         
         NOS2           rs2297518    Heterozygous     AG vs. AA/GG           0.49          0.35      0.70        6.32 × 10^-5^     
         GNAS            rs8386      Heterozygous     CT vs. TT/CC           0.67          0.47      0.95            0.024         
       G6PD~(F)~        rs1050828      Dominant       CT/TT vs. CC           2.47          1.34      4.56            0.003         
       G6PD~(M)~        rs1050828     Recessive       CC vs. CT/TT           3.01          1.26      7.18            0.009         
       G6PD~(F)~        rs1050829      Dominant       CT/TT vs. CC           1.88          1.20      2.93            0.005         
          CM           CD40LG~(F)~    rs3092945         Additive       TT vs. CT vs. CC    4.03      1.19            13.79          0.021
      CD40LG~(M)~       rs3092945      Additive     TT vs. CT vs. CC         4.03          1.18      13.79           0.021         
   Hyperparasitaemia      GBP7        rs1803632         Dominant         CG/CC vs. GG      0.53      0.29             0.96          0.041
          ABO           rs8176746    Heterozygous     AC vs. AA/CC           0.41          0.18      0.93            0.019         
         NOS2           rs8078340    Heterozygous     CT vs. CC/TT           1.80          1.01      3.21            0.046         
         DERL3          rs1128127     Recessive       AA vs. GA/GG           0.45          0.21      0.98            0.029         
     Hyperpyrexia         GBP7        rs1803632         Additive       GG vs. CG vs. CC    0.73      0.55             0.99          0.042
         CD36           rs3211938     Recessive       GG vs. GT/TT           2.80          1.20      6.51            0.027         
          ABO           rs8176746    Heterozygous     AC vs. AA/CC           0.61          0.37      1.01            0.045         
         RTN3           rs542998       Additive     TT vs. CT vs. CC         1.47          1.09      1.99            0.011         
         ADCY9         rs10775349      Additive     CC vs. CG vs. GG         0.02          0.01      0.04        1.35 × 10^-87^    
         EMR1           rs373533     Heterozygous     GT vs. GG/TT           1.86          1.22      2.84            0.003         
         EMR1           rs461645     Heterozygous     CT vs. CC/TT           1.75          1.15      2.67            0.008         
      CD40LG~(F)~       rs3092945      Dominant       CT/CC vs. TT           1.96          1.01      3.83            0.044         
       G6PD~(M)~        rs1050829     Recessive       CC vs. CT/TT           1.84          1.06      3.20            0.033         
          SMA             hHbS          rs334         Heterozygous       AT vs. TT/AA      0.34      0.13             0.93          0.024
         ADCY9          rs2230739    Heterozygous     AG vs. GG/AA           0.48          0.23      1.02            0.050         
         EMR1           rs461645      Recessive       TT vs. CT/CC           2.05          1.12      3.75            0.020         
          UM              NOS2        rs2297518       Heterozygous       GA vs. GG/AA      0.50      0.29             0.84          0.007
         NOS2           rs1800482     Recessive       GG vs. GC/CC           7.94          1.06      59.50           0.043         
         EMR1           rs461645       Additive     CC vs. CT vs. TT         1.42          1.04      1.93            0.025         

^**‡**^Additive, dominant, recessive and heterozygous advantage genotypic tests were performed, adjusted for age, sex, ethnicity and HbS, but only the most statistically significant result is presented. UM = uncomplicated malaria.

The presence of the rs2297518 SNP in the gene encoding *NOS2* was associated with protection from malaria infection (GG *vs.* AG *vs.* AA, OR = 0.52, 95%CI 0.36-0.75, p = 0.0005) (Additional file [1](#S1){ref-type="supplementary-material"}). In addition, individuals with the AG genotype of this SNP were protected from anaemia (OR = 0.49, 95%CI 0.35-0.70, p = 6.32 × 10^-5^) and UM (OR = 0.50, 95%CI 0.29-0.84, p = 0.007) (Table [2](#T2){ref-type="table"}). Furthermore, individuals with the rs10775349 SNP of *ADCY9* were protected from hyperpyrexia (CC *vs.* CG *vs.* GG, OR = 0.02, 95%CI 0.01-0.04, p = 1.35 × 10^-87^) while heterozygosity for the rs8176746 SNP in the *ABO* locus was associated with protection against hyperparasitaemia (AC *vs.* AA/CC, OR = 0.41, 95%CI 0.18-0.93, p = 0.019) (Table [2](#T2){ref-type="table"} and Additional file [2](#S2){ref-type="supplementary-material"}). Nevertheless, a number of marginal protective genotype associations were also observed between specific gene mutations and anaemia (*CFTR*, *GNAS*), hyperparasitaemia (*DERL3*, *GBP7*), hyperpyrexia (*GBP7*, *ABO*) and SMA (*HbS*, *ADCY9*) (Table [2](#T2){ref-type="table"}).

Male hemizygotes of *G6PD* rs1050828 (OR = 3.01, 95%CI 1.26-7.18, p = 0.009) and females with rs1050828 (CT/TT *vs.* CC, OR = 2.47, 95%CI 1.34-4.56, p = 0.003) and rs1050829 (CT/TT *vs.* CC, OR = 1.88, 95%CI 1.20-2.93, p = 0.005) SNPs of *G6PD* were more susceptible to anaemia (Table [2](#T2){ref-type="table"}). Heterozygous GT and CT individuals for the rs373533 (GT *vs.* GG/TT, OR = 1.86, 95%CI 1.22-2.84, p = 0.003) and rs461645 (CT *vs.* CC/TT, OR = 1.75, 95%CI 1.15-2.67, p = 0.008) SNPs respectively in the *EMR1* gene were more likely to develop hyperpyrexia. Furthermore, individuals with the *RTN3* rs542998 SNP (additive C, OR = 1.47, 95%CI 1.09-1.99, p = 0.011) were also independently associated with susceptibility to hyperpyrexia (Table [2](#T2){ref-type="table"}, Additional file [2](#S2){ref-type="supplementary-material"}). Even so, a number of marginal susceptibility genotype associations were also observed between specific gene mutations and anaemia (*GBP7*), CM (*CD40LG*), hyperparasitaemia (*NOS2*), hyperpyrexia (*CD36*, *CD40LG, G6PD*), SMA (*EMR1*) and UM (*NOS2*, *EMR1*) (Table [2](#T2){ref-type="table"}).

Additional file [2](#S2){ref-type="supplementary-material"} shows that some polymorphisms were associated with severe malaria only in individuals from the Semi-Bantu ethnic group. The sickle cell trait was significantly associated with protection from SMA \[AT *vs.* AA/TT, OR = 0.33, 95%CI 0.16-0.72, p = 0.003\] while individuals with the *EMR1* rs461645 TT and *NOS2* rs8078340 CT genotypes were more susceptible to SMA (OR = 2.79, 95%CI 1.30-6.02, p = 0.007) and hyperparasitaemia (OR = 2.91, 95%CI 1.24-6.83, p = 0.012) respectively. Conversely, the association between *G6PD* rs1050828 with anaemia in females (OR = 4.77, 95%CI 1.80-14.21, p = 0.003) was only observed in the Bantu ethnic group.

Plasma TGF-β levels were strongly correlated with heterozygosity for the *ADCY9* rs2230739 (p = 0.039) and *HBB* rs334 (p = 0.002) SNPs (Figure [2](#F2){ref-type="fig"}). Individuals with the AG genotype of the *ADCY9* gene had significantly higher levels of TGF-β compared to their AA and GG counterparts. Similarly, levels of the cytokine were higher in the AT heterozygotes of rs334 compared to their AA counterparts. Plasma IL-10 levels were also correlated with heterozygosity for the *ABO* rs8176746 (p = 0.011), with AC genotypes, however, having lower levels of the cytokine compared to their AA and CC counterparts. Nevertheless, no other SNPs were associated with levels of these cytokines.

![**Association between human cytokine genetic polymorphisms and plasma cytokine levels (pg/ml). A** = TGF-β and **B** = IL-10.](1475-2875-13-236-2){#F2}

Discussion
==========

The clinical outcome of human malaria infection is highly variable and heterogeneous, depending on many factors including age, transmission intensity, parasite strain virulence, co-infections with other pathogens, socio-economic status as well as the genetic background of the human host \[[@B40]\]. The human genome has, therefore, evolved under selective pressure exerted by pathogens, with human genetics thought to explain 25% of the inter-individual variation in susceptibility to and manifestation of malaria attributable to various host factors \[[@B3]\]. This natural selection process is epitomized in the historical exposure to *falciparum* malaria and its association with the β-globin SNP underlying the haemoglobin S sickle-cell trait \[[@B42]\]. This mutant allele, the strongest known resistance genetic factor, can reach a frequency of 25% in some populations in Sub-Saharan Africa \[[@B40]\] yet explains only 2% of the total variation \[[@B3]\]. Many unknown protective genes thus exist, each presumably individually having small population effects.

Genetic association studies utilising polymorphic markers in candidate genes have been successful in identifying a number of genes that are associated with susceptibility to malaria, or severe malaria. A large case--control study of severe malaria in children across different regions and major ethnic groups in Cameroon has the potential to confirm previously reported malaria/genetic associations or permit the identification of new ones following the assessment of association of SNPs of human genes with clinical phenotypes. This study focused on genes whose association with malaria remain controversial as well as those reportedly associated with susceptibility to other infectious diseases. This study suggests that the protective effect of the sickle cell trait may be linked to the raised level of TGF-ß and provides additional support for a role of *ABO* and *RTN3* against severe malaria. It further provides the first evidence that polymorphisms in *NOS2* and *EMR1* may be associated with mild malaria, *G6PD* with anaemia while SNPs in *ADCY9* and *EMR1* may be linked with severe malaria in the Cameroonian population. Data reported here provide additional understanding on human candidate genes that may contribute to malaria susceptibility, help define the basis of individual and population variation in susceptibility to the disease and thus eventually facilitate efforts to develop vaccines and treatments to fight this infectious disease. However, it is possible that an apparent association with malaria can arise from linkage disequilibrium between the typed SNP and a primarily associated polymorphism. Constructing a detailed map of polymorphisms around these candidate genes and describing a profile of linkage disequilibrium among them will be helpful to identify the causal variant(s). In addition, an appropriately designed family-based study may provide useful linkage information, have more power to detect association and allow haplotypes to be constructed with more confidence.

Although the CCTTT pentanucleotide microsatellite repeat in iNOS promoter is thought to play a key role in the pathogenesis of severe malaria \[[@B43]\], the protective effects for *NOS2* SNP is quite interesting since, no previous associations between rs2297518 and malaria have been reported. The SNP has, however, been linked with non-Hodgkin lymphoma \[[@B44]\] and inflammatory bowel disease \[[@B45]\]. It is possible that the SNP may increase the binding affinity to the mutant relative to the wild-type sequence thereby increasing the basal NOS activity and subsequent parasite killing by NO \[[@B15]\]. Parasites are thought to invade the liver, provoking a cytokine (e.g. IFN-γ) response that will induce *NOS2* to produce NO. The constitutively high NOS activity in children with the rs2297518 A allele will provide an advantage in resisting hepatic parasite stages without the need for additional stimuli. Nitric oxide is also thought to be effective in reducing blood-stage parasite density by antibody-dependent cellular inhibition \[[@B15]\] triggered by the ingestion of opsonised merozoites by activated monocytes. The latter may then release toxic products and NO acting on maturing intracellular and cytoadherent parasites to limit parasitaemia density.

Adenylate cyclase (AC) type 9 gene (*ADCY9*) is an interesting candidate gene since it is critical in neuronal signalling \[[@B46]\] and thus may be relevant in the pathogenesis of cerebral malaria. However, Toyota and colleagues reported only a weak association of *ADCY9* gene variation with mood disorders. Although the gene has polymorphisms with large allele frequency differences (*F*~*ST*~) between HapMap YRI and CEPH, the reported rs10775349 association with hyperpyrexia is very interesting. Nevertheless, further work is needed to strengthen these findings.

The observed association between Epidermal growth factor-like module containing, mucin-like, hormone receptor-like (EMR)1 polymorphisms and hyperpyrexia, severe malaria anaemia and uncomplicated malaria is quite interesting. *EMR1* is a macrophage marker and also a transmembrane glycoprotein present in peripheral blood mononuclear cells and presumably involved in cell-cell interactions and activation of consecutive messenger cascades \[[@B47]\]. Gene expression of *EMR1* is increased in lipoatrophic subcutaneous abdominal adipose tissue of HIV patients with HAART-associated lipodystrophy compared to those without \[[@B48]\] but no genetic associations with malaria have previously been reported. There is a need to explore further the possible role of this gene in malaria pathogenesis.

Polymorphisms in the ABO blood group were associated with hyperparasitaemia and hyperpyrexia (albert marginal) but not with the other more prevalent phenotypes. Previous studies have shown that cerebral malaria cases are less likely to be of blood group O \[[@B49],[@B50]\] but more likely to be of group AB in Sri Lanka \[[@B51]\] and type A and B in India \[[@B50]\] while reports from Gabon indicated reduced risk of severe malaria of blood group A individuals \[[@B52]\]. How, the heterozygotes remain refractory to extremely high parasitaemia and temperature levels is unclear. Further studies are required to elucidate the functional relevance of *ABO* variants on cytokines level.

Functional studies have demonstrated that a host erythrocyte G protein signal pathway may be a critical component in parasite invasion and that erythrocyte G-alpha-s protein and the malaria parasite interact at a cellular level \[[@B53]\]. It however remains unclear whether this interaction would impact on disease progression. The protective effect of rs8386 with anaemia observed in this study is in line with recent reports of an association between G-alpha-s gene (*GNAS*) polymorphisms with severe malaria \[[@B54]\], although the SNP was only significant in multi-locus associations.

Reticulon is thought to be involved in malaria pathogenesis since its gene expression significantly increases in malaria and other infections \[[@B11]\] while chloroquine affects its expression \[[@B55]\]. However, the association of rs542998 with hyperpyrexia is quite interesting since the SNP has recently been associated with malaria in a Tanzanian population \[[@B27]\]. Further studies are required to elucidate the role of this polymorphism with this and other syndromes of malaria.

Cytokine polymorphisms have previously been linked with their differential production and expression in malaria \[[@B5],[@B6]\], with variation in promoter sequences thought to alter specific transcription factor recognition sites, transcriptional activation and cytokine production \[[@B5]\]. However, the association between HbS rs334 and *ADCY9* rs2230739 with plasma levels of transforming growth factor-beta as well as *ABO* rs8176746 with interleukin-10 is quite interesting since resistance to severe malaria has been linked to the ability to produce these immuno-regulatory cytokines \[[@B21],[@B23]\]. How rs334 and rs8176746 affect TGF-β and IL-10 expression respectively is unclear. Nonetheless, *ADCY9* rs2230739 may act to upregulate TGFβ transcription, with the heterozygotes providing some selective advantage since the raised TGF-β levels will down-regulate proinflammatory cytokines, such as TNF, and protect against severe malaria \[[@B22],[@B23]\]. This, to our knowledge is the first report of such associations and thus needs to be explored further in different settings and with larger sample numbers. It should be noted that individual differences in the levels of the TGF-β measured at a specific moment may not only result from host genetic factors predisposing to high or low production, but also for a great part from the physiological condition at that time, as well as from global immunity.

Conclusions
===========

This study suggests that the protective effect of the sickle cell trait may be linked to the raised level of Transforming Growth Factor beta and provides additional support for a role of *ABO* and *RTN3* against severe malaria. It also provides the first evidence that polymorphisms in *NOS2* and *EMR1* may be associated with mild malaria, *G6PD* with anaemia while SNPs in *ADCY9* and *EMR1* may be linked with severe malaria in the Cameroonian population. Polymorphisms in human genes have important implications for the outcome of paediatric malaria in Cameroon. Moreover using mild malaria clinical phenotypes may permit the identification of novel pathways in the early development of disease.
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